Treatments preventing transplant rejection and their fantastic evolution

Organ transplantation began in years '60.

The intracellular mechanisms of rejection phenomenon is now well known.
Here you see the ways of lymphocytes activation.
These cells are part of the white cells that play the major cause in the course of rejection.

The, the treatments that are selectively active on the several successive steps of activation are shown hereafter:

Azathioprine (AZA) and cortisone were the only two medicines procured to the patients at that moment, but afterword, arround years 1980 was the cyclosporine (CsA) interduced.
The spectacular benefice of that treatment gave much better results in graft survival.
At the end of nineties, we got the mycophenolate mofetil (MMF or MPA) that could replace azathioprine, giving a new step in better results; we saw also the incoming of taco limbus (TRL) , some-more efficacious than CsA.

New technics gave the opportunity to induction treatment like monoclonal lymphocytes antibodies like basiliximab (Simulect) very well tolerated, much more than OKT3, and more than ATG, a polyclonal anti-lymphocyte antibody.

Now the efficacy of renal transplantation is 95% at one year, also with very good result for patient survival at one year (98%).
Patients are encouraged to be listed for a renal transplant when they are dialysed.
Kidney donation should be promoted.